Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. 
INTRODUCTION:
The OHSU Spellman/Gray work group is one of three collaborators funded by this Department of Defense Breast Cancer Multi-Team Award; the other two being comprised of the Lee work group from City of Hope (formerly of Stanford Medicine Cancer Institute) and the Slansky/Kappler work group from University of Colorado Denver/National Jewish Health. The major objective of this endeavor is to develop novel strategies aimed at the enhancement of the protective effects of anti-tumor T cells in vivo in a patient-specific manner based on the hypothesis that partially protective anti-tumor T cells exist within TDLNs in most breast cancer patients. This will be accomplished by identifying the antigens anti-tumor T cells target in different breast cancer subtypes, potentially including antigens preferentially expressed by breast cancer stem cells. We will identify both MHC-I-and MHC-II-restricted antigens driving both CD8 and CD4 anti-tumor T cells in vivo, as CD4 T cells are needed to optimally sustain vaccine-elicited CD8 T cells in vivo 1 . Identified antigens will be categorized as to breast cancer subtype-specificity or shared status amongst subtypes, with the intention a patient could be matched with an optimal set of vaccine antigens for her tumor. Another novel aspect of this project is the identification of altered peptides (mimotopes) that may more efficiently activate anti-tumor T cells than the natural tumor epitopes. A final objective is to identify small molecule anti-cancer agents that synergize with cytotoxic T lymphocytes (CTLs) to enhance immune-mediated killing. Collectively, this undertaking will produce a set of immunologically validated antigens and mimotopes for major breast cancer subtypes, and a set of agents that cooperate with immune killing. These can be used in combinations in a patient-specific manner to maximize clinical benefit while minimizing toxicity. The tools we develop will enhance the breadth and efficacy of existing and future approaches for immune therapy of breast cancer. We discuss here the Spellman/Gray group's specific efforts toward realizing the goals of this collaboration.
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OVERALL PROJECT SUMMARY:

Generation and initial analysis of T cell clones [Task 5]
Confirm tumor reactivity and HLA restriction of clones. Breast cancer therapy based on amplifying a patient's antitumor immune response depends on the availability of appropriate MHC class I-restricted, breast cancerspecific epitopes. To build a catalog of epitopes presented by breast cancer cells, we undertook systematic MHC class I immunoprecipitation followed by elution of MHC class I-loaded epitopes in breast cancer cell lines. MHC class I status in selected cell lines was also determined using RNA-seq analysis. The level of MHC class I mRNA expression is also presented in Table 1 . The data showed that in most cases, MHC class I staining (protein expression) did not correlate with the level of MHC class I mRNA. In addition, MHC class I staining was below the limit of detection in MDA-MB-157, JIMT1, CAL-51, ZR75B, SKBR3, and BT474 cells despite the fact that MHC class I mRNA was present in these cells. We identified MHC class I alleles in the breast cancer cell lines by RNA-seq using seq2HLA 4 to map RNA-seq reads against a reference database of HLA alleles 5 ( Table 1) . There was general agreement between HLA-A*02 phenotype and genotype; however, some cell lines were phenotypically HLA-A*02-negative although HLA-A*02 mRNA was present.
To identify MHC class I-restricted epitopes expressed on the cell surface MHC molecules were immunoprecipitated and epitopes were eluted by acid treatment. Eluates from control IgG and anti-MHC class I samples were subjected to mass spectrometry (MS) analysis. IgG control eluate from HCC1187 cells contained few peptides ( Fig. 2A) . In contrast, anti-MHC class I eluate from HCC187 contained several hundred peptides (Fig. 2B) . Immunoprecipitation and elution of peptides were repeated for all selected cell lines ( Table  1) in independent experiments.
We used the PAW processing pipeline 6 to identify cell surface peptides and control peptide false discovery rates. The total numbers of eluted peptides and corresponding proteins are shown in Table 2 . The data in Tables 1 and 2 suggest that high levels of cell surface MHC class I protein expression do not guarantee high levels of peptide loading. For example, despite three independent experiments, very few peptide epitopes were recovered from MDA-MB-231 cells, which expressed high levels of MHC class I. A total of 3,358 peptides derived from 3,070 proteins were eluted from MHC class I molecules immunoprecipitated from the surface of the 20 cell lines. After removal of duplicates, the total number of unique epitopes and corresponding proteins was 2,822 and 1,939, respectively. Next, we asked if the eluted epitopes contained mutated peptides, which are primary targets for T cell response. For this purpose we used specifically developed software, MS-Align+, which detects epitopes not only from normal proteins but also from mutated proteins and from proteins with new modifications 7 . We identified four epitopes derived from reverse translated genes tap1 (ATAPGLGGGPEPLGR) and ikbkap (EIISDPGVQGYSR) as well as from translations of a +1 frameshifted gene cp4 (AVASINSSEALR) and +2 frameshifted gene clipr1 (TAFESITSSDQR).
Analysis of our data showed that some peptides were most frequently presented on the cell surface of different breast cancer cell lines. As can be expected, peptides derived from proteins that are expressed at high levels in cancer and normal cells such as elongation factor 2 (EEF2), fructose-bisphosphate aldolase A (ALDOA), E3 ubiquitin-protein ligase RNF213 (RNF213), cytoplasmic dynein 1 heavy chain 1 (DYHC1), helicase with zinc finger domain 2 (HELZ2), and eukaryotic translation initiation factor 3 subunit D (EIF3D) were also most frequently presented in the context of MHC class I.
We also worked on the characterization of epitopes eluted from breast cancer cells. To find breast cancer specific MHC I-loaded epitopes that have the ability to activate T cell response, we selected a subset of the eluted epitopes. First, we selected epitopes from genes that have alterations in at least 20% of invasive breast cancers using the cBioPortal. These alterations included copy number amplification, homozygous deletion, mRNA upregulation or downregulation, and mutation. Second, we used gene expression data from 708 breast tumor and 329 normal tissues from TCGA, EBI, and GEO as well as from 62 breast carcinoma cell lines and 6 non-transformed cell lines to identify epitopes from genes that have preferential expression in breast cancer samples over normal samples (at least 4 fold difference). We also selected epitopes and genes that were frequently identified by our MHC I immunoprecipitation and elution approach among different cell lines (at least 4 times).
Total number of epitopes that met the above-described criteria was 467. We were interested in HLA-A2-restricted epitopes, because HLA-A2 allele is the most frequent allele in the US and Caucasian population. Using specific software we determined HLA-A2 binding score for each peptide and selected peptides that have score at least 20. The highest score is 36. Approximately, 170 peptides were selected and synthesized for further analysis.
To identify immunogenic peptides among selected peptides we used T cell activation protocol published in Blood (2007) 8 and J Immunol Methods (2006) 9 . Briefly, dendritic cells (DCs) were generated from HLA-A2-positive peripheral blood mononuclear cells (PBMCs) by a 90-min incubation at 37 °C in DC medium. Non-adherent cells and media were removed and replaced with 1 ml/well of fresh DC medium supplemented with 1000 IU/ml GM-CSF and 1000 IU/ml IL-4. After one day of incubation, DCs were matured using 10 ng/ml lipopolysaccharide (LPS) in the presence of peptide (10 g/ml). Next day, peptide pulsed DCs were irradiated (32 Gy) and mixed with autologous CD8+ T cells and incubated for 7 days. On the day 4, IL-2 (50IU/ml) and IL-7 (5 ng/ml) were added to the medium. This stimulation was repeated 3 times.
Secondary stimulation was set up as described above, except that artificial antigen-presenting C1R-A2 were used. This secondary stimulation was repeated 3 times. After final stimulation, T cells were harvested and used in INF- ELISA with C1R-A2 cells loaded with peptide. Figure  3 shows that peptide N 147 activates T cells as was evidenced by increased secretion of IFN- by T cells in the presence of peptide as compared to T cells without peptide or in the presence of HLA-A2 blocking antibodies.
The availability of comprehensive HLA-A, B, and C typing allowed us to predict the binding probability of each peptide to the HLA molecules present in the corresponding cells. For this purpose, we used a Consensus method 10 recommended by IEDB, which . The predicted affinity of each peptide was expressed as an IC50 value, which was expressed as a percentile rank, generated by comparing the peptide IC50 against those of a set of random peptides from the SWISSPROT database. Lower rank values indicate higher predicted peptide affinities. Next, we calculated a percentile rank of binding to HLA-A*02 for each peptide, and plotted the number of peptides (counts) in relation to these percentile ranks (Fig. 4) . We compared cell lines that were homozygous (MDA-MB-231, HCC1500, MCF7, and LY2), heterozygous (HCC1419, HCC1428, BT549, CAMA-1, MCF12A, UACC812, and SUM159PT), or null for HLA-A*02 based on the peptides that were derived from these cells in relation to percentile ranks (Fig. 4, inset) . The results suggested that approximately 50% of the eluted peptides in HLA-A*02-positive homozygous cell lines were presented by HLA-A proteins.
To predict the distribution of HLA-A*02-specific peptides in breast cancer cell lines, we used a beta distribution mixture model 17 , and fit the peptide distribution curve from the beta mixture model with Expectation Maximization (EM) implemented in Python. For HLA-A*02-negative cell lines, we modeled the data with one distribution to find the shape parameters for HLA-A*02-negative distribution. When modeling cell lines with an HLA-A*02-positive allele, we maximized the likelihood function to find the ratio between HLA-A*02-positive and HLA-A*02-negative alleles as well as the shape parameters for the HLA-A*02-positive distribution. This modeling process generated two beta distributions corresponding to HLA-A*02-positive and HLA-A*02-negative peptide distributions. In the follow up analysis, we determined the most likely proportion of HLA-A*02-positive peptides for each cell line from which we eluted at least 50 peptides ( Table 3 ). In addition, to determine if the eluted MHC class I-bound epitopes had been identified in previous studies, we searched the Immune Epitope Database (), which consists of 27,413 human unique peptide epitopes. We determined that of the 2,822 eluted unique epitopes, 803 ) in our data set were active in T cell activation assays (Table 4) . Surprisingly, we found that these immunogenic epitopes were seldom related to breast cancer, and two of them were previously identified as targets of T cells in chronic lymphocytic leukemia (CLL) patients. This analysis demonstrated that both established cancer cell lines can be used as a source for the identification of tumor specific and immunogenic epitopes and immunogenic epitopes can be shared between different cancer types including leukemia and solid tumor cells.
In addition, in the course of these studies, we collected tumors and normal tissue from 25 HLA-A2+ positive patients followed by total RNA purification and RNAseq analysis (exome sequencing). RNAseq analysis will be used to identify overexpressed genes and mutations that can be presented in HLA-A2-loaded epitopes. RNAseq data will facilitate identification of immunogenic epitopes from cancer patients. 
Cell line FDR HLA-A*02-HLA-A*02+
The CompleteTCR pipeline was constructed to determine the repertoire diversity of T cell receptor clones from raw next generation sequencing data. CompleteTCR is built on the foundation of the MiTCR open source software package developed by MiLaboratory. MiTCR is a highly efficient and rapid approach to CDR3 extraction, clonotype assembly, and repertoire diversity estimation while accounting for sequencing and PCR errors as well as salvaging low-quality input reads. Currently, MiTCR is limited to analysis of either the α chain or the β chain (human or mouse) of the TCR heterodimer. CompleteTCR enhances the capabilities of MiTCR by allowing determination of TCR clone repertoire diversity of the matched αTCR-βTCR complex using the raw TCR sequence data of individual T cells generated by the Denver work group. This is accomplished via downstream manipulation of MiTCR outputs using R 23 .
Since MiTCR assigns each input read a numeric identifier, it was necessary to make two modest changes to the MiTCR source code in order to produce the output required by CompleteTCR to match the α reads for each clonotype to their β mates. First, the standard MiTCR results file now includes a list of the numeric IDs for all reads belonging to each clonotype. Second, a temporary output file is created mapping the sequence identifier for each read in the input FASTQ file to its MiTCR-assigned numeric identifier. No changes were made to the algorithms MiTCR uses for CDR3 extraction, clonotype assembly, or error correction. The aforementioned R script first annotates the reads of each α clonotype with the appropriate sequence identifiers, repeating the process for the reads of each β clonotypes. The α and β reads are now paired according to their sequence identifier, and any read lacking a mate is removed from the dataset. Finally, the frequencies of αTCR-βTCR pairs, or clonotypes, are calculated.
This study resulted in the discovery of a TCR pair shared amongst 15 of 20 patient tumors and a number of other TCR pairs shared by 7 or more tumors. Since the TCR is examined ex vivo, data is not skewed by the effects of cell culture or cell death, lending confidence the shared TCR pairs are tumor-specific and hold potential as targets for immunotherapy. The false discovery rates of shared clonotypes was calculated, comparing the TCRs shared amongst the tumor PBMC samples to those shared amongst the normal/control PBMC samples. Of interest, we found the majority of statistically significant TCRs shared between the normal/control PBMC samples were absent from the entire set of tumor PBMC samples. Additional time was also spent ensuring any TCRs determined to be tumor-specific are, in fact, absent in the controls.
The OHSU team was also employed by the Denver team to perform additional computationally intensive analyses. For example, a custom script was designed to identify and quantify palindromic nucleic acid sequences residing in insertions at the VJ, VD, and DJ junctions of each clone identified (more than once) by CompleteTCR. These nucleotides, making up all or part of an insertion, inversely repeat the immediately adjacent germline DNA sequence.
Interpretations and implications of results from each study described in this section were performed by the Denver team and are currently in publication. We have made the CompleteTCR software package and source code freely available to the research community under a GNU license via GitHub . It is run from the command line via a shell wrapper script that requires an input manifest detailing locations of the α and β FASTQ files as well as their corresponding sample names. This approach facilitates high throughput data processing.
RNAseq analysis of tumor cells [Task 7]
RNAseq analysis to identify breast cancer-specific aberrant transcripts. Publically and privately available RNAseq datasets were used to conduct a systematic computational analysis identifying aberrant transcripts resulting in breast cancer antigens. The Spellman computational group developed an epitope prediction pipeline utilizing approximately 1000 breast cancer and normal tissue RNAseq samples available through The Cancer Genome Atlas (TCGA) 26 , European Bioinformatics Institute (EBI) comprised of breast, lung, liver, brain, heart, kidney, and B-cells. A variety of other tissues are also represented, albeit in smaller sample numbers, to include bowel, skeletal muscle, lymph node, and ovary, amongst others. The entirety of the tumor dataset was obtained from the TCGA Data Portal. Of the better than 700 tumor samples, TCGA categorized approximately 460 samples into basal, Her2, and luminal subtypes using the PAM-50 subtype prediction method 29 , enabling evaluation of subtype specificity of predicted transcripts. Only sequences generated on the Illumina Genome Analyzer II and Genome Analyzer IIx 30 platforms were included in the study to maintain as much uniformity as possible between datasets generated at different locations. As many of the sequences were single-end reads and read lengths varied from 50-150bp, the FASTQ files for all paired-end sequences were converted to single-end, and read lengths were trimmed as necessary to 50bp prior to submission to the analytical pipeline ( Figure 5 ). Initial mining of the RNAseq dataset was implemented via the Bowtie/Tophat/Cufflinks 3,31,32 packages (collectively referred to as the Tuxedo suite) to carry out sequence assembly and alignment to the human genome (hg19), prediction of novel isoforms, and quantitation of transcript structure. Using the Cuffmerge 3 feature of Cufflinks, the entire set of assemblies were merged such that identical transcripts across all samples were accounted for by a single identifier and its associated gene expression values.
Novel isoforms of a transcript can indicate alternative splicing events not yet characterized by the reference genome as well as aberrant structural variations due to mutation, both of which can result in neoantigens. Due to very low representation of the novel isoforms in some samples, it is likely the Tuxedo suite may not have detected, assembled, and subsequently determined the expression level for the new isoform in every sample. In order to force Tuxedo to look for and calculate the expression values of all isoforms in each sample, the subset of transcripts predicted to be novel assemblies were extracted from the Cuffmerge output and used to construct a new transcriptome index. The entire RNAseq dataset was rerun through the Tuxedo suite using this new index as the reference sequence. From here on, the collections of native and novel transcripts are kept separate from each other but run in parallel through the remainder of the pipeline. . This function accounts for distribution differences by matching the count distribution quantiles between samples, as described in 33 and 34 . Differential expression was evaluated across all normal and tumor samples by calculating the Median Split Silhouette (MSS) of each gene. MSS is a clustering algorithm measuring the average heterogeneity of possible clusters and determines whether the expression profile of a gene, across all normal and tumor samples, is best described by one or more clusters 35 . The advantage of MSS comes from its ability to identify biologically meaningful clusters where cluster size may be small. For our purposes, we limited the maximum number of potential clusters to three (kmax=3) in order to capture any distinction of gene expression between normal and tumor tissues as well as any Originally, the strongest transcript candidates were selected by setting arbitrary cutoffs on percentage of tumor population and expression level represented in a cluster of interest. Transcripts failing to meet the set criteria were discarded. As we are also interested in where known immunogenic transcripts fall within the entire dataset, adjustments were made to the epitope discovery pipeline to establish 1) an enhanced method of ranking transcripts and epitopes with regard to expression specificity in tumor over normal tissues and 2) an automated workflow for discerning the unique portions of novel isoform sequences in large batches, rather than interrogating them individually.
To this end, a heuristic equation for expression ranking was established to calculate the rank of every candidate exhibiting a bimodal (high and low) or trimodal (high, mid, and low) expression profile across all samples. The equation is designed to highlight tumor-specific transcripts by placing higher weight on those where the high expression (H) cluster: 
Complement Normal Population Fraction (CNPFx) = [1 -( NS H ⁄ NP H )]
4) Exhibits a significantly higher expression value than the low expression cluster as indicated by the difference between the unlogged medoid expression value of the high expression cluster (EV H ) and the of the low expression cluster (EV L )
Expression Difference (ED) = αlog(EV H ) -αlog (EV L )
The priority ranking of each transcript candidate is then determined by:
Transcript Rank = TFx * TPFx * CNPFx * ED
The ranked novel assemblies now undergo translation potential assessment to elucidate those sequences possessing the best potential for translation into unique peptide constructs. The coding sequence of each transcript is translated in all three frames using the EMBOSS transeq tool 37, 38 , and the longest open reading frame (ORF) is selected. This sequence is aligned to the peptide sequences for all transcripts of the hg19 reference gene most closely related to the novel isoform using EMBL-EBI Clustal Omega 39 and EMBOSS showalign 37 . Any candidate lacking a start site shared by at least one of the reference sequences or possessing an ORF identical to any of the reference transcripts is removed from the dataset. Of the remaining candidates, the unique portion(s) of each transcript are aligned to the entire hg19 reference genome using BLAT 40 , and any sequence(s) found to align elsewhere in the genome are also discarded. As longer candidate epitope sequences provide more opportunity for a true immunologic target, the remaining transcripts undergo epitope candidate ranking (Fig. 1) to take the length of the potential epitope into account.
Epitope Rank = Transcript Rank * Candidate Epitope Length
Twenty of the top-ranked known transcripts ( Table 5A ) and twenty of the top-ranked novel epitopes (Table 5B) are listed in Table 5 . A number of the known transcripts provided in Table 5A are already known to be associated with breast cancer. The miR492 and miR622 micro-RNAs are found to have expression signatures correlated with specific breast cancer subtypes 41 , and miR492 is particular is associated with supporting hepatic cancer progression through targeting of PTEN 42 . The cellular retinoic acid binding protein (CRABP2) is jointly regulated with estrogen receptor alpha and retinoic acid receptor alpha in human breast cancer cells 43 . The guanine nucleotide-binding protein subunit beta-2-like 1 (GNB2L1, or RACK1) has been reported as a predictor for pool clinical outcome in breast cancer patients and has potential to be an independent biomarker for diagnosis and prognosis of breast cancer. Upregulation of S100A11 is reported in a variety of metastatic cancers and is essential for the efficient repair of the plasma membrane and for the survival of highly motile cancer cells 44 , while overexpression of S100A14 modulates HER2 signaling in breast cancer 45 . Interferon alpha-inducible protein 6 (IFI6, or G1P3) promotes hyperplasia, tamoxifen resistance, and poor patient outcomes in breast cancer 46 . The estrogen-responsive anterior gradient 2 (AGR2) influences dissemination of metastatic breast cancer cells and may be useful as a marker in identification of circulating tumor and metastatic cells in sentinel lymph nodes. It is also a promising drug target and prognostic indicator 46 .
The prevalence of breast cancer associated genes residing in high-ranking positions of this dataset lends significant support to the functionality of our pipeline as well as validity to the top-ranking epitope candidate results (Table 5B ). In fact, even amongst the top-ranked epitope candidates shown in Table 5B , there are a number of cancer-related genes, including thymosin beta-10 (TMSB10, G-actin sequestration and breast Table 5 . Twenty of the top ranked known (A) and novel (B) transcript candidates predicted by the epitope discovery pipeline in terms of 'transcript rank' for known transcripts and 'epitope rank' for predicted epitope sequence of novel isoforms.
cancer cell motility) 48 , keratin 18 (KRT18, tumor dedifferentiation and loss of estrogen and progesterone receptors) 48 , and annexin A2 (ANXA2, invasion augmentation of multidrug-resistant breast tumor cells) 50 .
As the predicted peptide sequence of a number of these candidates is the result of a single nucleotide change, sequencing of the aberrant region would be required for validation. Upon further inspection, the majority of the single nucleotide differences were determined to occur only at splice junctions, suggesting their prediction could be the result of erroneous alignment by Tophat, specifically alignment of 1-3 bases at the end of the read to the adjacent intron rather than to the correct position(s) at the beginning of the next exon. This issue has been addressed and corrected by more current spliced alignment programs, such as GSNAP, STAR, and Tophat2; however, the our dataset was originally aligned with Tophat in early 2013, overlapping the release date of Tophat2.
Before committing laboratory resources to candidate validation, we have chosen to reanalyze the TCGA breast tumors using an alternative alignment algorithm, Spliced Transcripts Alignment to Reference (STAR), to eliminate candidates predicted from poor splice junction alignment. This second pass of analysis involves the inclusion of a substantial number of additional RNA sequences to the original set of approximately 700 breast tumors (TCGA) and nearly 370 normal tissues (TCGA, GEO, EBI). We incorporated RNA sequence data for an additional >400 TCGA breast tumors, nearly 300 TCGA normal tissues, and >1700 GTEx normal tissues. This expansion of our normal tissue dataset provides an even more robust resource of normal transcript expression levels across all tissues against which tumors are compared for identification of uniquely expressed transcripts. With a dataset now more than double the original, along with the challenges encountered using an older alignment algorithm, it is imperative we reduce the computational resources required while improving alignment accuracy. To this end, implementation of STAR v2.4.2a for alignment to the most current version of the human reference genome (GRCh38) will have similar alignment accuracy and a runtime a fraction of that of Tophat2. The remainder of the pipeline remains unchanged. This analysis is still in progress. Candidates predicted via the epitope discovery pipeline, with support from both the Tophat and STAR algorithms, will be validated in the laboratory.
The current epitope candidate portfolio developed from this study is available upon request.
Identify small molecule agents enhancing tumor cell apoptosis and CTL killing [Task 12]
As outlined in Aim 4 of the proposal, clinical efficacy of T cell-based therapies will be enhanced in combination with agents promoting tumor cell apoptosis. Support for this idea recently has been published showing chemotherapy can synergize with CTL-mediated killing 51 ; however, chemotherapeutic agents can also inhibit T cell function.
We are continuing our work in this area to identify drugs nontoxic to normal cells by developing T cell cytotoxicity assays using the peptides we previously characterized (see Task 5 above). We have determined the printing of Con A to specific spots on a slide allows attachment of PBMCs to these spots (Fig. 6) . We also show attachment to Con A does not affect cell functionality, such as cell proliferation rate and ability of siRNA to reduce gene expression.
Finally, we designed a protocol to personalize T cell-based treatment (Fig. 7) . In this protocol, we will perform MHC I immunoprecipitation and epitope elution from patient tumor tissue, as we did with the breast carcinoma cell lines, followed by mass spectrometry analysis. Tumor-specific epitopes will be selected by gene expression analysis of the corresponding proteins. These epitopes, altogether with Con A, will be printed on a slide. Next, we will extract PBMCs and cytotoxic T lymphocytes (CTLs) from the same patient and allow the PBMCs to bind to the Con A spotted slide. Because the PBMCs are from the same patient, we do not need to know the type of MHC I alleles present in the patient. The slide, with attached PBMCs, will then be incubated with the patient's CTLs, and T cell activation will be detected using IFN-γ, CD137, CD107, and other T cell activation markers. We plan to test this protocol using tumors from breast cancer patients consented to the project by the City of Hope working group.
KEY RESEARCH ACCOMPLISHMENTS:
 Determined which of the 170 MHC I-loaded eluted epitopes identified in the previous funded year exhibited the ability to activate T cells. Eleven sequences were characterized as immunogenic, several of which were found in multiple cell lines.  Modified open source MiTCR software to allow matching sequence reads from the alpha and beta chains of a single TCR followed by calculation of clonotype frequencies. Input to the program is raw sequence data from single TCRs generated by the Slansky team. The software is repackaged as CompleteClone.  Modified the epitope discovery pipeline developed in the previous funding year for in silico prediction of breast cancer epitopes from RNAseq data. A more robust method for transcript and neoantigen candidate prioritization was instituted, and an automated approach for validating transcription potential of novel isoforms and isolation of potential neoantigen sequences was developed.  Designing a protocol for personalization of T cell-based therapy through direct observation of tumorderived T cell activation against epitopes eluted from the same patient. 
